The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Retigabine (Trobalt®) has been accepted for restricted use as an adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and above. The restriction limits use to individuals with refractory epilepsy with treatment initiated by clinicians who have appropriate experience in the treatment of epilepsy.
Prucalopride (Resolor®) has been rejected for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. The manufacturer failed to provide a sufficiently robust clinical and economic analysis. The National Institute for Health and Clinical Excellence (NICE) has previously recommended the product provided that at least two different types of laxatives at the highest possible recommended doses for at least 6 months without success and invasive treatment is being considered.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« BNF for Children 2011-2012||New Contra-indications and Warnings for Pioglitazone »|